Cargando…
Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice
BACKGROUND AND AIM: The morbidity and mortality of Shigella infections remain a global challenge. Epitope-based vaccine development is an emerging strategy to prevent bacterial invasion. This study aimed to identify the ability of the 49.8 kDa pili subunit adhesin protein epitope of Shigella flexner...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Veterinary World
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980390/ https://www.ncbi.nlm.nih.gov/pubmed/35400957 http://dx.doi.org/10.14202/vetworld.2022.281-287 |
_version_ | 1784681381785239552 |
---|---|
author | Anam, Khoirul Endharti, Agustina Tri Poeranto, Sri Sujuti, Hidayat Hidayati, Dwi Yuni Nur Prawiro, Sumarno Reto |
author_facet | Anam, Khoirul Endharti, Agustina Tri Poeranto, Sri Sujuti, Hidayat Hidayati, Dwi Yuni Nur Prawiro, Sumarno Reto |
author_sort | Anam, Khoirul |
collection | PubMed |
description | BACKGROUND AND AIM: The morbidity and mortality of Shigella infections remain a global challenge. Epitope-based vaccine development is an emerging strategy to prevent bacterial invasion. This study aimed to identify the ability of the 49.8 kDa pili subunit adhesin protein epitope of Shigella flexneri to induce an intestinal immune response in mice. MATERIALS AND METHODS: Thirty adult male Balb/c mice were divided into a control group, cholera toxin B subunit (CTB) group, CTB+QSSTGTNSQSDLDS (pep_1) group, CTB+DTTITKAETKTVTKNQVVDTPVTTDAAK (pep_2) group, and CTB+ ATLGATLNRLDFNVNNK (pep_3). We performed immunization by orally administering 50 μg of antigen and 50 μl of adjuvant once a week over 4 weeks. We assessed the cellular immune response by quantifying T helper 2 (Th2) and Th17 using flow cytometry. In addition, we assessed the humoral immune response by quantifying interleukin (IL-4), IL-17, secretory immunoglobulin A (sIgA), and β-defensin using enzyme-linked immunoassay. Statistical analysis was performed using one-way analysis of variance and Kruskal–Wallis test. RESULTS: Peptide oral immunization increases the cellular immune response as reflected by the increase of Th2 (p=0.019) and Th17 (p=0.004) cell counts, particularly in the CTB_pep_1 group. Humoral immune response activation was demonstrated by increased IL-4 levels, especially in the CTB+pep_3 group (p=0.000). The IL-17 level was increased significantly in the CTB+pep_1 group (p=0.042). The mucosal immune response was demonstrated by the sIgA levels increase in the CTB+pep_3 group (p=0.042) and the β-defensin protein levels (p=0.000). CONCLUSION: All selected peptides activated the cellular and humoral immune responses in the intestine of mice. Further studies are necessary to optimize antigen delivery and evaluate whether the neutralizing properties of these peptides allow them to prevent bacterial infection. |
format | Online Article Text |
id | pubmed-8980390 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Veterinary World |
record_format | MEDLINE/PubMed |
spelling | pubmed-89803902022-04-08 Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice Anam, Khoirul Endharti, Agustina Tri Poeranto, Sri Sujuti, Hidayat Hidayati, Dwi Yuni Nur Prawiro, Sumarno Reto Vet World Research Article BACKGROUND AND AIM: The morbidity and mortality of Shigella infections remain a global challenge. Epitope-based vaccine development is an emerging strategy to prevent bacterial invasion. This study aimed to identify the ability of the 49.8 kDa pili subunit adhesin protein epitope of Shigella flexneri to induce an intestinal immune response in mice. MATERIALS AND METHODS: Thirty adult male Balb/c mice were divided into a control group, cholera toxin B subunit (CTB) group, CTB+QSSTGTNSQSDLDS (pep_1) group, CTB+DTTITKAETKTVTKNQVVDTPVTTDAAK (pep_2) group, and CTB+ ATLGATLNRLDFNVNNK (pep_3). We performed immunization by orally administering 50 μg of antigen and 50 μl of adjuvant once a week over 4 weeks. We assessed the cellular immune response by quantifying T helper 2 (Th2) and Th17 using flow cytometry. In addition, we assessed the humoral immune response by quantifying interleukin (IL-4), IL-17, secretory immunoglobulin A (sIgA), and β-defensin using enzyme-linked immunoassay. Statistical analysis was performed using one-way analysis of variance and Kruskal–Wallis test. RESULTS: Peptide oral immunization increases the cellular immune response as reflected by the increase of Th2 (p=0.019) and Th17 (p=0.004) cell counts, particularly in the CTB_pep_1 group. Humoral immune response activation was demonstrated by increased IL-4 levels, especially in the CTB+pep_3 group (p=0.000). The IL-17 level was increased significantly in the CTB+pep_1 group (p=0.042). The mucosal immune response was demonstrated by the sIgA levels increase in the CTB+pep_3 group (p=0.042) and the β-defensin protein levels (p=0.000). CONCLUSION: All selected peptides activated the cellular and humoral immune responses in the intestine of mice. Further studies are necessary to optimize antigen delivery and evaluate whether the neutralizing properties of these peptides allow them to prevent bacterial infection. Veterinary World 2022-02 2022-02-11 /pmc/articles/PMC8980390/ /pubmed/35400957 http://dx.doi.org/10.14202/vetworld.2022.281-287 Text en Copyright: © Anam, et al. https://creativecommons.org/licenses/by/4.0/Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Anam, Khoirul Endharti, Agustina Tri Poeranto, Sri Sujuti, Hidayat Hidayati, Dwi Yuni Nur Prawiro, Sumarno Reto Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice |
title | Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice |
title_full | Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice |
title_fullStr | Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice |
title_full_unstemmed | Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice |
title_short | Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice |
title_sort | shigella flexneri vaccine development: oral administration of peptides derived from the 49.8 kda pili protein subunit activates the intestinal immune response in mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980390/ https://www.ncbi.nlm.nih.gov/pubmed/35400957 http://dx.doi.org/10.14202/vetworld.2022.281-287 |
work_keys_str_mv | AT anamkhoirul shigellaflexnerivaccinedevelopmentoraladministrationofpeptidesderivedfromthe498kdapiliproteinsubunitactivatestheintestinalimmuneresponseinmice AT endhartiagustinatri shigellaflexnerivaccinedevelopmentoraladministrationofpeptidesderivedfromthe498kdapiliproteinsubunitactivatestheintestinalimmuneresponseinmice AT poerantosri shigellaflexnerivaccinedevelopmentoraladministrationofpeptidesderivedfromthe498kdapiliproteinsubunitactivatestheintestinalimmuneresponseinmice AT sujutihidayat shigellaflexnerivaccinedevelopmentoraladministrationofpeptidesderivedfromthe498kdapiliproteinsubunitactivatestheintestinalimmuneresponseinmice AT hidayatidwiyuninur shigellaflexnerivaccinedevelopmentoraladministrationofpeptidesderivedfromthe498kdapiliproteinsubunitactivatestheintestinalimmuneresponseinmice AT prawirosumarnoreto shigellaflexnerivaccinedevelopmentoraladministrationofpeptidesderivedfromthe498kdapiliproteinsubunitactivatestheintestinalimmuneresponseinmice |